Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 13, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 2,804 Ordinary Shares by Abacus (GSK) Trustees Limited, acting as trustee of the GlaxoSmithKline Employee Trust ("the GSK Trust"). These shares were transferred to participants in the SmithKline Beecham Employee Option Plan 1991 on September 12, 2005.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items beyond this standard trust administration were disclosed.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust to assess the impact of the 2,804 share transfer.
- Confirm the specific allocation of shares to participants in the SmithKline Beecham Employee Option Plan 1991.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure complete compliance regarding director interests.